97 related articles for article (PubMed ID: 4086873)
1. Prostatic malignancy.
Paulson DF
J Urol (Paris); 1985; 91(7):401-7. PubMed ID: 4086873
[No Abstract] [Full Text] [Related]
2. Total androgen suppression: are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma.
Foote JE; Crawford ED
Semin Urol; 1988 Nov; 6(4):291-302. PubMed ID: 3068767
[No Abstract] [Full Text] [Related]
3. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer.
Hennenfent BR
Br J Urol; 1998 Jul; 82(1):166. PubMed ID: 9698691
[No Abstract] [Full Text] [Related]
4. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
6. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
Uphoff J; Woziwodzki J; Schattka SO; Kollias A
Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
[TBL] [Abstract][Full Text] [Related]
7. [Cyproterone acetate. Its value in the treatment of prostatic cancer. Apropos of 45 cases].
Tobelem G; Arvis G
Therapie; 1988 May; 43(3):179-82. PubMed ID: 2971278
[No Abstract] [Full Text] [Related]
8. Prostate cancer: non-metastatic.
Wilt T
Clin Evid; 2002 Jun; (7):812-23. PubMed ID: 12230707
[No Abstract] [Full Text] [Related]
9. Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate.
Seay TM; Blute MC; Zincke H
Urology; 1997 Dec; 50(6):833-7. PubMed ID: 9426709
[No Abstract] [Full Text] [Related]
10. [Prostatic carcinoma].
Weingärtner K; Gerharz EW; Riedmiller H
Dtsch Med Wochenschr; 1994 Feb; 119(7):235-43. PubMed ID: 7508847
[No Abstract] [Full Text] [Related]
11. Histopathological effects of androgen deprivation in prostatic cancer.
Civantos F; Soloway MS; Pinto JE
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
[TBL] [Abstract][Full Text] [Related]
12. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Rogers C
J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14575038
[No Abstract] [Full Text] [Related]
13. Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.
Lotan Y
Eur Urol; 2007 Aug; 52(2):453-4. PubMed ID: 17674436
[No Abstract] [Full Text] [Related]
14. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense?
Schulman CC; Wildschutz TP
Acta Urol Belg; 1996 May; 64(2):57-61. PubMed ID: 8701814
[No Abstract] [Full Text] [Related]
16. [Clinical impact of neoadjuvant treatment to radical prostatectomy in locally advanced prostatic cancer].
Villavicencio H; Laguna P; Ponce de Léon J
Actas Urol Esp; 1994 May; 18 Suppl():404-8. PubMed ID: 8073926
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer (non-metastatic).
Wilt T
Clin Evid; 2003 Dec; (10):1023-38. PubMed ID: 15555136
[No Abstract] [Full Text] [Related]
18. Antiandrogen therapy and side effects following radical prostatectomy.
Clin J Oncol Nurs; 2000; 4(4):179-80. PubMed ID: 11261099
[No Abstract] [Full Text] [Related]
19. Prostate cancer (non-metastatic).
Wilt T
Clin Evid; 2003 Jun; (9):973-85. PubMed ID: 12967402
[No Abstract] [Full Text] [Related]
20. [LHRH agonists in prostate cancer].
Rossi D; Cornu JN; Rouprêt M
Prog Urol; 2007 Apr; 17(2 Suppl 1):287-90. PubMed ID: 17569272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
